

Freedom of Information Request	FOI 22-408	22 nd September 2022
--------------------------------	------------	---------------------------------

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

- Bevacizumab (Avastin)
- Dacarbazine (DTIC)
- Trametinib (Mekinist)
- Dabrafenib (Tafinlar)
- Ipilimumab (Yervoy)
- Vemurafenib (Zelboraf)
- Nivolumab (Opdivo)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Pembrolizumab (Keytruda)
- Vemurafenib + cobimetinib (Zelboraf + Cotellic)
- Dabrafenib + Trametinib (Tafinlar + Mekinist)
- Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
- Other active systemic anti-cancer therapy [please state]
- Palliative care only

The Health Board is only able to provide information by quantity and not by patient or diagnosis.

Please find below quantities dispensed via hospital pharmacies for the above listed drugs for the period June 2022 to August 2022.

Description	Quantity
DACARBAZINE 200 mg Intravenous Injection 10 Vial Pack	13

Melanoma treatments are delivered by [Velindre University NHS Trust](#), therefore you will need to contact via the link provided.

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

- Ipilimumab
- Ipilimumab AND Nivolumab
- Nivolumab
- Pembrolizumab
- Dabrafenib AND Trametinib
- Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy
- Palliative care only

The Health Board is only able to provide information by quantity and not by patient and diagnosis. None of the above drugs have been dispensed via hospital pharmacies for the above listed drugs for the period June 2022 to August 2022.